BCLI P/E Ratio
P/E Ratio as of Jun 13, 2025: -0.56
Average-0.5924
Median-0.5700
Minimum-0.6900
Maximum-0.5400
-0.56
Past Month+0.02 (3.45%)
The P/E ratio for BCLI is -0.56 as of Jun 13, 2025. This represents a decrease of -29.11% compared to its 12-month average P/E ratio of -0.79. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
Brainstorm Cell Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Brainstorm Cell Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Brainstorm Cell Therapeutics to industry peers.
Brainstorm Cell Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
Brainstorm Cell Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing Brainstorm Cell Therapeutics to industry peers.
BCLI P/E Ratio Insights
See Brainstorm Cell Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in BCLI
Order type
Buy in
Order amount
Est. shares
0 shares
BCLI P/E Ratio Historic Data
| Date | Stock price | P/E ratio |
|---|---|---|
| Jun 2, 2025 | $1.11 | -0.56 |
| May 1, 2025 | $1.16 | -0.50 |
| Apr 1, 2025 | $1.19 | -0.51 |
| Mar 3, 2025 | $1.56 | -0.45 |
| Feb 3, 2025 | $1.835 | -0.53 |
| Jan 2, 2025 | $2.14 | -0.61 |
BCLI End of Year P/E Ratio
| Date | P/E ratio | Change |
|---|---|---|
| 2025 | -0.56 | -13.85% |
| 2024 | -0.65 | +3.17% |
| 2023 | -0.63 | -73.19% |
| 2022 | -2.35 | -60.30% |
| 2021 | -5.92 | +37.35% |
| 2020 | -4.31 | — |
FAQs About Brainstorm Cell Therapeutics (BCLI) P/E ratio
The latest P/E ratio of BCLI is -0.56, as of Jun 13, 2025. This is calculated based on its current stock price and earnings per share (EPS).
Brainstorm Cell Therapeutics’s last 12-month average P/E ratio is -0.79, compared to its current P/E ratio of -0.56. This reflects a decrease of -29.11%.
Brainstorm Cell Therapeutics’s current P/E ratio of -0.56 is lower than its last 12-month average P/E of -0.79. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
Brainstorm Cell Therapeutics’s average P/E ratio over the last 3 years is -2.15. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
Brainstorm Cell Therapeutics’s average P/E ratio over the last 5 years is -3.7. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.